Compare Lululemon Athletica Inc (LULU) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lululemon Athletica Inc vs Sanofi SA — how do they compare? Lululemon Athletica Inc trades at $113.65 (market cap $13.24B), while Sanofi SA trades at $43.89 (market cap $104.85B). The key difference: Sanofi SA is far larger — about 7.9× Lululemon Athletica Inc's market cap, and Sanofi SA pays a 5.53% dividend while Lululemon Athletica Inc pays none. Which is the better fit depends on your goals.
| LULU | SNY | |
|---|---|---|
Market Cap | $13.24B | $104.85B |
Sector | Consumer Cyclical | Health |
52-Week High | $224.03 | $52.34 |
52-Week Low | $105.43 | $41.33 |
Enterprise Value | $13.87B | $121.38B |
Dividend Yield | — | 5.53% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lululemon trades at $116.63, up 0.26% today, amid bearish technical signals but strong fundamentals. The stock shows consistent earnings beats, with Q1 2026 EPS of $1.69 exceeding the $1.67 estimate. Revenue grew to $10.59B in 2025, with a net income margin of 17.13%. Recent news includes a $30M investment in nylon recycling startup Syntetica and resolution of a proxy battle with founder Chip Wilson, boosting shareholder confidence.
The outlook is mixed: valuation metrics like a P/E of 9.45 and EV/EBITDA of 5.41 suggest potential upside to the $129.29 consensus target, but technical bearishness and competitive pressures pose risks. Investors may find value in robust profitability and strategic initiatives, though macroeconomic headwinds and brand controversies require monitoring.
SNY trades at $43.76, down 2.02% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 results pending. Revenue grew to $46.72B in 2025, with net income margin improving to 16.72%. Recent positive developments include FDA approval for Sarclisa's wearable injector and EU approval for Cenrifki in multiple sclerosis.
Outlook remains positive with analyst consensus leaning toward buy/hold, though regulatory scrutiny in the EU presents near-term risk. The stock offers a solid dividend yield with the upcoming $2.42 payment. Valuation metrics like P/E of 19.5 and P/B of 1.27 suggest reasonable pricing relative to peers, supported by robust cash flow from operations of $10.75B.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lululemon Athletica Inc
Lululemon Athletica Inc. designs, distributes, and markets athletic apparel, footwear, and accessories for women, men, and girls. Lululemon offers pants, shorts, tops, and jackets for both leisure and athletic activities such as yoga and running. The company also sells fitness accessories, such as bags, yoga mats, and equipment. Lululemon sells its products through more than 600 company-owned stores in 18 countries, e-commerce, outlets, and wholesale accounts. The company was founded in 1998 and is based in Vancouver, Canada.
Read more on LULU →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
